Jaguar Gene Therapy
Shouryadeep Srivastava currently serves as the Senior Vice President of Clinical Development at Actym Therapeutics, Inc., since March 2024, where the focus is on developing innovative therapeutic solutions for cancer patients. Concurrently, Shouryadeep is involved as a Clinical Advisor and Clinical Development Consultant for Jaguar Gene Therapy. Previously, Shouryadeep held the position of Vice President of Clinical Development at Theseus Pharmaceuticals from January 2023 to November 2023, contributing to various clinical trials before the company underwent significant workforce reductions. Past roles include Vice President of Clinical Development at iTeos Therapeutics, Senior Medical Director at Takeda Oncology, and Global Clinical Development Lead at Shire, with extensive experience in leading clinical strategy and execution across multiple therapeutic areas, including oncology and hematology. Shouryadeep holds an MBBS from Baba Raghav Das Medical College and a PhD in Pharmacology & Neuroscience from Texas Tech University Health Sciences Center.
This person is not in any offices
Jaguar Gene Therapy
Jaguar Gene Therapy is accelerating breakthroughs in gene therapy for patients suffering from severe genetic diseases. Led by the former AveXis leadership team and backed by Deerfield Management, a healthcare-specific investment firm, Jaguar brings streamlined R&D, manufacturing and clinical operations to accelerate development and potential approval of therapies for severe genetic diseases.